Oxler Private Wealth LLC Buys 1,270 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Oxler Private Wealth LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 279.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,725 shares of the company’s stock after buying an additional 1,270 shares during the quarter. Oxler Private Wealth LLC’s holdings in IDEXX Laboratories were worth $931,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Gotham Asset Management LLC lifted its stake in IDEXX Laboratories by 79.9% in the third quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock valued at $7,620,000 after buying an additional 7,741 shares in the last quarter. NewEdge Wealth LLC lifted its stake in IDEXX Laboratories by 30.4% in the third quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock valued at $279,000 after buying an additional 149 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of IDEXX Laboratories by 25.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after purchasing an additional 8,831 shares in the last quarter. Carderock Capital Management Inc. lifted its position in shares of IDEXX Laboratories by 35.7% in the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after purchasing an additional 4,315 shares in the last quarter. Finally, Mitchell Capital Management Co. lifted its position in shares of IDEXX Laboratories by 1.3% in the third quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock worth $2,786,000 after purchasing an additional 79 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX stock traded down $11.63 during midday trading on Tuesday, hitting $518.44. The company’s stock had a trading volume of 486,416 shares, compared to its average volume of 452,925. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The stock has a market cap of $42.82 billion, a price-to-earnings ratio of 50.19, a PEG ratio of 4.28 and a beta of 1.27. The stock’s 50-day moving average price is $511.06 and its 200 day moving average price is $522.11. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40.

Insiders Place Their Bets

In other news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction on Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares in the company, valued at $87,068.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.18% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 14th. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Barclays lowered their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, May 14th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $580.38.

Get Our Latest Research Report on IDEXX Laboratories

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Read More

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.